Tools
Stock profile

Syndax Pharmaceuticals Inc (SNDX)

SNDX · Latest close $8.56 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$8.56
As of Nov 18, 2026
Tracked funds holding
3 of 149
2026 Q2 13F filings
Opened / added
0 / 2
vs previous quarter
Trimmed / exited
0
vs previous quarter

Syndax Pharmaceuticals Inc (SNDX) is held by 3 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds adding versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $113.7K sold). Latest close $8.56 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 29, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-113.7K
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Deerfield Management · OrbiMed Advisors · Torray Investment Partners LLC — 3 tracked funds hold SNDX. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 1 sale ($113.7K). Insider trading

Often held alongside

Edwards Lifesciences Corp (EW) · Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Deerfield Management0.86%3,779,900HELD Q3 filed Nov 16
OrbiMed Advisors0.62%1,542,000ADDED (+60.2%) Q3 filed Nov 16
Torray Investment Partners LLC0.39%133,835ADDED (+27.6%) Q3 filed Oct 30

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -56.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

25.157.902024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding242 of 8,857 filers
Long-only filers among them241
Change vs 2026 Q1+5 net · 233 entered · 228 exited
Shares reported, all filers108,057,153
Reported value, all filers$2.4B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$172.4M
Net income · FY2025$-285.4M
Total assets · FY2025$529.7M
Shares outstanding89,297,086
Market cap (at latest close)$764.4M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 31, 2026.

Short interest

Shares short · Oct 15, 202618,001,644
Share of shares outstanding20.16%
Days to cover7.64

Shares short at recent settlements — Jul 31, 2026: 22.7M · Aug 14, 2026: 22.9M · Aug 31, 2026: 21.7M · Sep 15, 2026: 20.7M · Sep 30, 2026: 18.2M · Oct 15, 2026: 18.0M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 31, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 4K · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 31, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 1 sale by 1 insider ($113.7K).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Oct 29, 2026Podlesak DennisSell8,000$14.21$113.7KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jul 8, 2026MICHAEL METZGERDirector, Officer32,375$752.4KJul 8, 2026SEC filing
Jun 12, 2026Botwood Nicholas A.J.Officer31,235$566.7KJun 12, 2026SEC filing
Jun 11, 2026Botwood Nicholas A.J.Officer34,280$609.4KJun 11, 2026SEC filing
Jun 1, 2026Goldan Keith A.Officer1,177$22.4KJun 1, 2026SEC filing
Jun 1, 2026Metzger Michael AOfficer, Director6,847$130.0KJun 1, 2026SEC filing
Feb 9, 2026Metzger Michael AOfficer, Director17,159$360.8KFeb 9, 2026SEC filing
Feb 9, 2026Goldan Keith A.Officer3,410$71.7KFeb 9, 2026SEC filing
Feb 6, 2026Metzger Michael AOfficer, Director7,412$152.8KFeb 6, 2026SEC filing
Feb 6, 2026Goldan Keith A.Officer2,082$42.9KFeb 6, 2026SEC filing
Sep 8, 2025MICHAEL METZGERDirector, Officer157,307$2.7MSep 8, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 7, 2026STATE STREET CORPORATIONSC 13G5,658,4656.4%Jun 30, 2026SEC filing
May 15, 2026Point72 Asset Management, L.P.SC 13G/A1,985,5472.3%Mar 31, 2026SEC filing
Apr 30, 2026Vanguard Capital ManagementSC 13G4,457,1435.0%Mar 31, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 9, 2026STATE STREET CORPORATIONSC 13G4,596,5525.3%Dec 31, 2025SEC filing
Jan 30, 2026The Vanguard GroupSC 13G/A6,230,3347.2%Dec 31, 2025SEC filing
Aug 18, 2025Point72 Asset Management, L.P.SC 13G4,327,9525.0%Aug 15, 2025SEC filing
Aug 14, 2025Point72 Asset Management, L.P.SC 13G/A2,307,8242.7%Jun 30, 2025SEC filing
Aug 13, 2025THE GOLDMAN SACHS GROUP, INC.SC 13G/A5,581,828.066.5%Jun 30, 2025SEC filing
May 9, 2025THE GOLDMAN SACHS GROUP, INC.SC 13G/A4,510,669.265.2%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 3 Lobbying Disclosure Act filings named this company as client, 2020–2020; most common issues: Health Issues (3), Government Issues (3).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

· Excess Accruals (Sloan) — Sloan accruals ratio beyond ±25%

Key figures

· Distress Risk (Altman Z″) — Z″-Score: -7.54 · Working capital / assets: 0.77 · Retained earnings / assets: -2.84 · EBIT / assets: -0.52 · Equity / liabilities: 0.14

· Excess Accruals (Sloan) — Accruals ratio: -47.7% · Net income: $-285.4M · Operating cash flow: $-323.0M · Investing cash flow: $290.0M

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2025 Q2, ranked #23 of 50.

Also held by the tracked funds that hold SNDX — ranked by lift, the co-holding pattern described in Methodology: Edwards Lifesciences Corp (EW) · Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT).

7 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 2, 20262.02 Results of Operations and Financial Condition · 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 9.01 Financial Statements and ExhibitsSEC filing
Aug 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jul 14, 20268.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Edwards Lifesciences Corp (EW) · Track Record: how the signals scored · Practice timing on SNDX

One email a week: the week’s new filings and research. Subscribe free

← SNDK  ·  SNEX →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.